MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$389,605K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from issuance of conver...
Maturities of marketable securit...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-644,371
-453,816
-364,892
-766,409
Loss on disposal of fixed assets
-
-
0
-32
Amortization of intangible assets
-
0
69
801
Stock-based compensation expense
67,000
87,299
33,696
84,693
Depreciation and amortization
2,449
2,346
2,267
5,513
Change in fair value of warrant liability
151,031
15,788
12,627
2,731
Non-cash interest expense on liabilities related to sale of future royalties
22,899
12,197
11,937
12,294
Non-cash interest expense on convertible senior notes
880
-
-
-
Net amortization of premium or discount on marketable securities
4,333
3,223
4,554
23,277
Amortization of operating lease right-of-use asset
2,051
2,189
2,366
5,542
Impairment of assets
-
-
-
0
Accounts receivable
-
-
0
0
Prepaid expenses and other current assets
30,540
10,471
3,377
6,290
Accounts payable
5,031
16,857
-10,501
20,036
Accrued expenses and other current liabilities
55,783
-16,739
54,604
57,663
Deferred revenue
-
-
0
-
Operating lease liability
-2,135
-2,073
241
-1,198
Deferred tax liability
-
-
0
-
Long-term deposits
7,745
10,561
7,297
4,723
Other noncurrent assets
-
-
154
12,718
Other prepaid and noncurrent assets
-95
378
-
-
Other noncurrent liabilities
-5,224
5,664
-1,270
1,807
Net cash used in operating activities
-387,319
-354,165
-274,238
-623,503
Purchases of marketable securities
2,038,361
209,733
296,485
1,498,365
Maturities of marketable securities
381,977
383,886
373,292
1,549,222
Sales of marketable securities
0
-
0
6,384
Purchases of property and equipment
2,286
1,538
1,925
14,065
Net cash provided by (used in) investing activities
-1,658,670
172,615
74,882
43,176
Proceeds from issuance of common stock, net of issuance costs
1,651,355
-
0
-
Cash, cash equivalents and restricted cash acquired in connection with eqrx acquisition, net of transaction costs
-
-
0
-
Proceeds from issuance of pre-funded warrants, net of transaction costs
-
-
0
-
Proceeds from the sale of future royalties, net of issuance costs
245,000
-
0
244,215
Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs
0
226,730
347,915
0
Proceeds from issuance of convertible senior notes, net
487,068
-
-
-
Proceeds from issuance of common stock pursuant to stock option exercises
-
-
21,134
-
Proceeds from issuance of common stock under equity incentive plans
28,844
5,236
-
6,973
Proceeds from issuance of common stock related to employee stock purchase plan
8,473
-
3,392
4,644
Tax payment for common stock withheld in satisfaction of withholding tax requirements
-
-
0
-
Proceeds from exercise of warrants
236
57
0
4
Deferred offering costs
491
252
-191
-29
Net cash provided by financing activities
2,420,485
238,744
365,659
255,865
Net increase (decrease) in cash, cash equivalents and restricted cash
374,496
57,194
166,303
-324,462
Cash, cash equivalents and restricted cash - beginning of period
445,797
388,603
222,300
546,762
Cash, cash equivalents and restricted cash - end of period
820,293
-
-
-
Cash and cash equivalents
815,435
-
-
-
Restricted cash
4,858
-
-
-
Cash, cash equivalents and restricted cash - end of period
820,293
445,797
388,603
222,300
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$1,651,355K
Proceeds from issuance of
convertible senior notes,...
$487,068K
Proceeds from the sale of
future royalties, net...
$245,000K
Proceeds from issuance of
common stock under...
$28,844K
Proceeds from issuance of
common stock related to...
$8,473K
Proceeds from exercise of
warrants
$236K
Net cash provided by
financing activities
$2,420,485K
Canceled cashflow
$491K
Net increase
(decrease) in cash, cash...
$374,496K
Canceled cashflow
$2,045,989K
Deferred offering costs
$491K
Maturities of marketable
securities
$381,977K
Change in fair value of
warrant liability
$151,031K
Stock-based compensation
expense
$67,000K
Accrued expenses and
other current...
$55,783K
Non-cash interest
expense on liabilities...
$22,899K
Accounts payable
$5,031K
Depreciation and
amortization
$2,449K
Amortization of operating
lease right-of-use...
$2,051K
Non-cash interest
expense on convertible...
$880K
Net cash provided by
(used in) investing...
-$1,658,670K
Net cash used in
operating activities
-$387,319K
Canceled cashflow
$381,977K
Canceled cashflow
$307,124K
Purchases of marketable
securities
$2,038,361K
Net loss
-$644,371K
Purchases of property and
equipment
$2,286K
Prepaid expenses and
other current assets
$30,540K
Long-term deposits
$7,745K
Other noncurrent
liabilities
-$5,224K
Net amortization of
premium or discount on...
$4,333K
Operating lease liability
-$2,135K
Other prepaid and
noncurrent assets
-$95K
Buy us a coffee
Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc. (RVMD)